Precision BioSciences reports positive Phase 1 hepatitis B trial data showing viral DNA elimination

Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read

Key Changes

• high

  PBGENE-HBV achieved 10-fold reduction in viral DNA transcripts by directly eliminating cccDNA, the persistent form of hepatitis B virus in liver cells, demonstrating the drug's mechanism works in humans.

  Item 7.01: Press Release verify on EDGAR →
• high

  All six patients with measurable pgRNA at baseline achieved complete elimination of this biomarker, validating a blood test that can replace invasive liver biopsies to measure treatment effectiveness in future trials.

  Item 7.01: Clinical Data verify on EDGAR →
• high

  No dose-limiting toxicities observed across 38 doses in 16 patients; most side effects were temporary infusion reactions resolving within 24 hours.

  Item 7.01: Safety Profile verify on EDGAR →